Drug Profile
Research programme: Tc 99m DTPA glipizide - CellPoint
Alternative Names: Tc 99m DTPA glipizide - CellPointLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator CellPoint
- Class Radiopharmaceutical diagnostics
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus(Diagnosis) in USA
- 24 Jan 2012 CellPoint's entire portfolio of products under development licensed to Radiopharmacus in Brazil
- 12 Jul 2011 Preclinical trials in Diabetes mellitus in USA (unspecified route)